<DOC>
	<DOCNO>NCT02700334</DOCNO>
	<brief_summary>Prediabetes term refers alteration glucose homeostasis , include impaired fasting glucose ( IFG ) , impair glucose tolerance ( IGT ) , involve high risk progression type 2 diabetes mellitus ( T2DM ) . Dapagliflozin selective reversible inhibitor sodium-glucose type 2 ( SGLT-2 ) co-transporter , reduce renal glucose reabsorption promotes glucose excretion urine , blood glucose improve patient T2DM . Although mechanism independent insulin , evidence improve secretion insulin sensitivity , interest assess effect patient prediabetes , potential therapy treat disorder prevent progression T2DM . The aim study evaluate effect Dapagliflozin insulin secretion insulin sensitivity patient prediabetes . The investigator hypothesis administration dapagliflozin improve insulin secretion insulin sensitivity patient prediabetes .</brief_summary>
	<brief_title>Effect Dapagliflozin Insulin Secretion Insulin Sensitivity Patients With Prediabetes</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled clinical trial 24 patient diagnosis prediabetes accordance American Diabetes Association ( ADA ) without treatment . They assign randomly two group 12 patient receive 10 mg Dapagliflozin ( Forxiga , Astra Zeneca ) placebo , one per day breakfast 12 week . There calculated Area Under Curve glucose insulin , total insulin secretion ( Insulinogenic index ) , first-phase insulin secretion ( Stumvoll index ) insulin sensitivity ( Matsuda index ) . This protocol 's already approve local ethic committee write informed consent 's go obtained volunteer . Statistical analysis present measure central tendency dispersion , average deviation standard quantitative variable ; frequency percentages variable qualitative . Qualitative variable analyze X2 , use difference inter-group Mann-Whitney U Test Wilcoxon Test within-groups difference . It consider statistical significance p ≤0.05 . This protocol approve local ethic committee write informed consent obtain volunteer .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients sexes Age 30 60 year Diagnosis prediabetes accord ADA criterion ( fast blood glucose level 100126 mg/dl ; postprandial blood glucose level oral glucose tolerance test 75 oral glucose 140199 mg/dl ; glycosylated hemoglobin 5.76.4 % ) Informed consent sign Women confirm suspected pregnancy Women lactation and/or puerperium Hypersensibility ingredients intervention Physical impossibility take pill Known uncontrolled renal , hepatic , heart thyroid diseased Diabetes diagnosis Previous treatment glucose Body Mass Index ≥35 kg/m2 Triglycerides ≥500 mg/dL Total cholesterol ≥240 mg/dL Low density lipoprotein ( cLDL ) ≥190 mg/dL Blood Pressure ≥140/90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prediabetes</keyword>
	<keyword>Impaired fasting glucose</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Impaired glucose tolerance</keyword>
	<keyword>Glucose intolerance</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>Sodium glucose cotransporter 2 inhibitor</keyword>
	<keyword>SGLT2</keyword>
</DOC>